Association study of polymorphisms in the alpha 7 nicotinic acetylcholine receptor subunit and catechol-o-methyl transferase genes with sensory gating in first-episode schizophrenia

Psychiatry Research

Volumn 209, Issue 3, 2013, Pages 431-438

  Liu, Xia ^a,b   Hong, Xiaohong ^a   Chan, Raymond C K ^c   Kong, Fanzhi ^a   Peng, Zhizhen ^a,d   Wan, Xiaona ^a,e   Wang, Changqing ^a,f   Cheng, Lu ^g  

^a SHANDONG MENTAL HEALTH CENTER   (China)

^b Mental Health Hospital of Jining   (China)

^c INSTITUTE OF PSYCHOLOGY   (China)

^d The Third People's Hospital of Zhongshan   (China)

^e The Seventh Hospital of Qingdao   (China)

^f Chronic Diseases Hospital at Baoan District of Shenzhen   (China)

^g Southeast University   (China)

Author keywords

Auditory evoked potential P50; CHRNA7; COMT; Patients with first episode schizophrenia; Prepulse inhibition of startle reflex

Indexed keywords

BUNGAROTOXIN RECEPTOR; CATECHOL METHYLTRANSFERASE;

ADOLESCENT; ADULT; ARTICLE; CHRNA7 GENE; COMT GENE; CONTROLLED STUDY; ENDOPHENOTYPE; EVOKED AUDITORY RESPONSE; FEMALE; FIRST EPISODE SCHIZOPHRENIA; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; PREPULSE INHIBITION; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY GATING; SENSORY SYSTEM ELECTROPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; STARTLE REFLEX; WILD TYPE;

AUDITORY EVOKED POTENTIAL P50; CHRNA7; COMT; PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA; PREPULSE INHIBITION OF STARTLE REFLEX;

ACOUSTIC STIMULATION; ADOLESCENT; ADULT; ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; CATECHOL O-METHYLTRANSFERASE; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS, AUDITORY; FEMALE; GAIT DISORDERS, NEUROLOGIC; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INHIBITION (PSYCHOLOGY); MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84885473019     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.03.027     Document Type: Article

References (72)

1. Adler L.E., Hoffer L.D., Griffith J., Waldo M.C., Freedman R. Normalization by nicotine of deficient auditory sensory gating in the relatives of schizophrenics. Biological Psychiatry 1992, 32:607-616.
2. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. American Journal of Psychiatry 1993, 150:1856-1861.
3. Bhakta S.G., Zhang J.P., Malhotra A.K. The COMT Met158 allele and violence in schizophrenia: a meta-analysis. Schizophrenia Research 2012, 140:192-197.
4. Bickford P.C., Wear K.D. Restoration of sensory gating of auditory evoked response by nicotine in fimbria-fornix lesioned rats. Brain Research 1995, 705:235-240.
5. Braff D., Stone C., Callaway E., Geyer M., Glick I., Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978, 15:339-343.
6. Braff D.L., Light G.A., Ellwanger J., Sprock J., Swerdlow N.R. Female schizophrenia patients have prepulse inhibition deficits. Biological Psychiatry 2005, 57:817-820.
7. Braff D.L., Freedman R., Schork N.J., Gottesman I.I. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophrenia Bulletin 2007, 33:21-32.
8. Bramon E., Rabe-Hesketh S., Sham P., Murray R.M., Frangou S. Meta-analysis of the P300 and P50 waveforms in schizophrenia. Schizophrenia Research 2004, 70:315-329.
9. Bray N.J., Buckland P.R., Williams N.M., Williams H.J., Norton N., Owen M.J., O'Donovan M.C. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. American Journal of Human Genetics 2003, 73:152-161.
10. Brenner C.A., Edwards C.R., Carroll C.A., Kieffaber P.D., Hetrick W.P. P50 and acoustic startle gating are not related in healthy participants. Psychophysiology 2004, 41:702-708.
11. Cadenhead K.S., Swerdlow N.R., Braff D.L. Relative risk of prepulse inhibition deficits in schizophrenia patients and their siblings. Biological Psychiatry 2001, 49:126S.
12. Cadenhead K.S., Light G.A., Shafer K.M., Braff D.L. P50 Suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment. Biological Psychiatry 2005, 57:1504-1509.
13. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., Weinberger D.R. Functional analysis of genetic variation in catechol-o-methyltransferase (COMT): Effects on mRNA, protein, and enzyme activity in postmortem human brain. American Journal of Human Genetics 2004, 75:807-821.
14. Clementz B.A., Geyer M.A., Braff D.L. P50 suppression among schizophrenia and normal comparison patients: a methodological analysis. Biological Psychiatry 1997, 41:1035-1044.
15. Couturier S., Bertrand D., Matter J.M., Hernandez M.C., Bertrand S., Millar N., Valera S., Barkas T., Ballivet M. A neuronal nicotinic acetylcholine receptor subunit (alpha 7) is developmentally regulated and forms a homo-oligomeric channel blocked by alpha-BTX. Neuron 1990, 5:847-856.
16. Dean B. The cortical serotonin 2A receptor and the pathology of schizophrenia: a likely accomplice. Journal of Neurochemistry 2003, 85:1-13.
17. Duncan E.J., Madonick S.H., Parwani A., Angrist B., Rajan R., Chakravorty S., Efferen T.R., Szilagyi S., Stephanides M., Chappell P.B., Gonzenbach S., Ko G.N., Rotrosen J.P. Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 2001, 25:72-83.
18. Erwin R.J., Turetsky B.I., Moberg P., Gur R.C., Gur R.E. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophrenia Research 1998, 33:157-167.
19. Freedman R., Adler L.E., Bickford P., Byerley W., Coon H., Cullum C.M., Griffith J.M., Harris J.G., Leonard S., Miller C. Schizophrenia and nicotinic receptors. Harvard Review Psychiatry 1994, 2:179-192.
20. Geyer M.A., Krebs-Thomson K., Braff D.L., Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 2001, 156:117-154.
21. Goff D.S., Henderson D.C., Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. American Journal of Psychiatry 1992, 149:1189-1194.
22. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. American Journal of Psychiatry 2003, 160:636-645.
23. Hall M-H., Schulze K., Rijsdijk F., Picchioni M., Ettinger U., Bramon E., Freedman R., Murray R.M., Sham P. Heritability and reliability of P300, P50 and duration mismatch negativity. Behavioural Genetics 2006, 36:845-857.
24. Hamera E., Schneider J.K., Deviney S. Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia. Journal of Nervous and Mental Disease 1995, 183:559-565.
25. Hong X., Chan R.C., Zhuang X., Jiang T., Wan X., Wang J., Xiao B., Zhou H., Jiang L., Weng B. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia. Schizophrenia Research 2009, 108:151-157.
26. Houy E., Raux G., Thibaut F., Belmont A., Demily C., Allio G., Haouzir S., Fouldrin G., Petit M., Frebourg T., Campion D. The promoter-194C polymorphism of the nicotinic alpha 7 receptor gene has a protective effect against the P50 sensory gating deficit. Molecular Psychiatry 2004, 9:320-322.
27. http://www.ncbi.nlm.nih.gov/projects/snp.
28. Huang M.X., Edgar J.C., Thoma R.J., Hanlon F.M., Moses S.N., Lee R.R., Paulson K.M., Weisend M.P., Irwin J.G., Bustillo J.R., Adler L.E., Miller G.A., Canive J.M. Predicting EEG responses using MEG sources in superior temporal gyrus reveals source asynchrony in patients with schizophrenia. Clinical Neurophysiology 2003, 114:835-850.
29. Jacobsen L.M., Schistad E.I., Storesund A., Pedersen L.M., Rygh L.J., Røe C., Gjerstad J. The COMT rs4680 Met allele contributes to long-lasting low back pain, sciatica and disability after lumbar disc herniation. European Journal of Pain 2012, 16:1064-1069.
30. Lanni C., Garbin G., Lisa A., Biundo F., Ranzenigo A., Sinforiani E., Cuzzoni G., Govoni S., Ranzani G.N., Racchi M. Influence of COMT Val158Met polymorphism on Alzheimer's disease and mild cognitive impairment in Italian patients. Journal of Alzheimer's Disease 2012, 32:919-926.
31. Laruelle M., Kegeles L.S., Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Annals of New York Academy Sciences 2003, 1003:138-158.
32. Leumann L., Feldon J., Vollenweider F.X., Ludewig K. Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biological Psychiatry 2002, 52:729-739.
33. Leonard S., Adams C., Breese C.R., Adler L.E., Bickford P., Byerley W., Coon H., Griffith J.M., Miller C., Myles-Worsley M., Nagamoto H.T., Rollins Y., Stevens K.E., Waldo M., Freedman R. Nicotinic receptor function in schizophrenia. Schizophrenia Bulletin 1996, 22:431-445.
34. Leonard S., Gault J., Hopkins J., Logel J., Vianzon R., Short M., Drebing C., Berger R., Venn D., Sirota P., Zerbe G., Olincy A., Ross R.G., Adler L.E., Freedman R. Association of promoter variants in the alpha 7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. Archives General Psychiatry 2002, 59:1085-1096.
35. Lewis D.A., Melchitzky D.S., Sesack S.R., Whitehead R.E., Auh S., Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. Journal of Comparative Neurology 2001, 432:119-136.
36. Li G.C., Wan X.N., Hong X. Study of the prepulse inhibition of startle reflex in first-episode schizophrenics. Journal of Shantou University Medical College 2010, 23:39-41.
37. Lu B.Y., Martin K.E., Edgar J.C., Smith A.K., Lewis S.F., Escamilla M.A., Miller G.A., Cañive J.M. Effect of catechol O-methyltransferase val158met polymorphism on the p50 gating endophenotype in schizophrenia. Biological Psychiatry 2007, 62:822-825.
38. Ludewig K., Geyer M.A., Etzensberger M., Vollenweider F.X. Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophrenia Research 2002, 55:129-137.
39. Luntz-Leybman V., Bickford P.C., Freedman R. Cholinergic gating of response to auditory stimuli in rat hippocampus. Brain Research 1992, 587:130-136.
40. Mackeprang T., Kristianscn K.T., Glenthoj B.Y. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients. Biological Psychiatry 2002, 52:863-873.
41. Mann C., Croft R.J., Scholes K.E., Dunne A., O'Neill B.V., Leung S., Copolov D., Phan K.L., Nathan P.J. Differential effects of acute serotonin and dopamine depletion on prepulse inhibition and p50 suppression measures of sensorimotor and sensory gating in humans. Neuropsychopharmacology 2008, 33:1653-1666.
42. Montag C., Hartmann P., Merz M., Burk C., Reuter M. D2 receptor density and prepulse inhibition in humans: negative findings from a molecular genetic approach. Behavioural Brain Research 2008, 187:428-432.
43. Murphy K.C. Schizophrenia and velo-cardio-facial syndrome. Lancet 2002, 359:426-430.
44. Myles-Worsley M., Coon H., Byerley W., Waldo M, Young D, Freedman R Developmental and genetic influences on the P50 sensory gating phenotype. Biological Psychiatry 1996, 39:289-295.
45. Myles-Worsley M. P50 sensory gating in multiplex schizophrenia families from a Pacific Island isolate. American Journal of Psychiatry 2002, 159:2007-2012.
46. Oranje B., van Berckel B.N.M., Kemner C., van Ree J.M., Kahn R.S., Verbaten M.N. P50 suppression and prepulse inhibition of the startle reflex in humans: a correlational study. Biological Psychiatry 1999, 45:883-890.
47. Oranje B., Geyer M.A., Bocker K.B.E., Leon Kenemans J., Verbaten M.N. Prepulse inhibition and P50 suppression: commonalities and dissociations. Psychiatry Research 2006, 143:147-158.
48. Parwani A., Duncan E., Bartlett E., Madonick S., Efferen T.R., Rajan R., Sanfilipo M., Chappell P.B., Chakravorty S., Gonzenbach S., Ko G.N., Rotrosen J.P. Impaired prepulse inhibition of acoustic startle in schizophrenics. Biological Psychiatry 2000, 47:662-669.
49. Peng Z.Z., Wan X.N., Jiang T.Y., Cheng L., Sun B.L., Hong X.H. Association between neuronal nicotinic acetylcholine receptor α7 subunit gene polymorphism and schizophrenia. Journal of Shantou University Medical College 2007, 20:213-219.
50. Peng Z.Z., Wan X.N., Jiang T.Y., Cheng L., Sun B.L., Hong X.H. The transmission disequilibrium analysis between neuronal nicotinic acetylcholine receptor alpha 7 subunit gene polymorphisms and schizophrenia. Zhong Hua Yi Xue Yi Chuan Xue Za Zhi 2008, 25:154-158.
51. Postma P., Gray J.A., Sharma T., Geyer M., Mehrotra R., Das M., Zachariah E., Hines M., Williams S.C., Kumari V. A behavioural and functional neuroimaging investigation into the effects of nicotine on sensorimotor gating in healthy patients and persongs with schizophrenia. Psychopharmacology 2006, 184:589-599.
52. Quednow B.B., Schmechtig A., Ettinger U., Petrovsky N., Collier D.A., Vollenweider F.X., Wagner M., Kumari V. Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyl transferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biological Psychiatry 2009, 66:614-620.
53. Quednow B.B., Wagner M., Mössner R., Maier W., Kühn KU. Sensorimotor gating of schizophrenia patients depends on catechol o-methyltransferase Val158Met polymorphism. Schizophrenia Bulletin 2010, 36:341-346.
54. Ross R.G., Stevens K.E., Proctor W.R., Leonard S., Kisley M.A., Hunter S.K., Freedman R., Adams C.E. Research review: cholinergic mechanisms, early brain development, and risk for schizophrenia. Journal of Child Psychology and Psychiatry 2010, 51:535-549.
55. Raux G., Bonnet-Brilhault F., Louchart S., Houy E., Gantier R., Levillain D., Allio G., Haouzir S., Petit M., Martinez M., Frebourg T., Thibaut F., Campion D. The 2bp deletion in exon 6 of the alpha 7-like nicotinic receptor subunit gene is a risk factor for the P50 sensory gating deficit. Molecular Psychiatry 2002, 7:1006-1011.
56. Roussos P., Giakoumaki S.G., Rogdaki M., Pavlakis S., Frangou S., Bitsios P. Prepulse inhibition of the startle reflex depends on the catechol-o-methyltransferase Val158Met gene polymorphism. Psychological Medicine 2008, 8:1-8.
57. Schwarzkopf S.B., Lamberti J.S., Smith D.A. Concurrent assessment of acoustic startle and auditory P50 evoked potential measures of sensory inhibition. Biological Psychiatry 1993, 33:815-828.
58. Shaikh M., Hall M.H., Schulze K., Dutt A., Walshe M., Williams I., Constante M., Picchioni M., Toulopoulou T., Collier D., Rijsdijk F., Powell J., Arranz M., Murray R.M., Bramon E. Do COMT, BDNF and NRG1 polymorphisms influence P50 sensory gating in psychosis?. Psychological Medicine 2011, 41:263-276.
59. Shifman S, Bronstein M., Sternfeld M., Pisante-Shalom A., Lev-Lehman E., Weizman A., Reznik I., Spivak B., Grisaru N., Karp L., Schiffer R., Kotler M., Strous R.D., Swartz-Vanetik M., Knobler H.Y., Shinar E., Beckmann J.S., Yakir B., Risch N., Zak N.B., Darvasi A. A highly significant association between a COMT haplotype and schizophrenia. American Journal of Human Genetics 2002, 71:1296-1302.
60. Stephens S.H., Logel J., Barton A., Franks A., Schultz J., Short M., Dickenson J., James B., Fingerlin T.E., Wagner B., Hodgkinson C., Graw S., Ross R.G., Freedman R., Leonard S. Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia. Schizophrenia Research 2009, 109:102-112.
61. Stevens K.E., Meltzer J., Rose G.M. Nicotinic cholinergic normalization of amphetamine-induced loss of auditory gating in freely moving rats. Psychopharmacology 1995, 119:163-170.
62. Stevens K.E., Freedman R., Collins A.C., Hall M., Leonard S., Marks M.J., Rose G.M. Genetic correlation of inhibitory gating of hippocampal auditory evoked response andalpha-bungarotoxin-bindingnicotinic cholinergic receptors in inbred mouse strains. Brain Research 1996, 15:152-162.
63. Stevens K.E., Kem W.R., Mahnir V.M., Freedman R. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology 1998, 136:320-327.
64. Swerdlow N.R., Braff D., Geyer M. Animal models of deficient sensorimotor gating: what we know, what we think we know, and what we hope to know soon. Behavioural Pharmacology 2000, 11:185-204.
65. Tunbridge E.M., Harrison P.J., Weinberger D.R. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biological Psychiatry 2006, 60:141-151.
66. Wan X.N., Jiang T.Y., Jiang L.Y., Hong X.H. Studies on the auditory sensory gating potential P50 in the first-episode schizophrenics and their first-degree relatives. Chinese Journal Nervous Mental Diseases 2007, 33:444-445.
67. Weike A.I., Bauer U., Hamm A.O. Effective neuroleptic medication removes prepulse inhibition deficits in schizophrenia patients. Biological Psychiatry 2000, 47:61-70.
68. Weinshilboum R.M., Otterness D.M., Szumlanski C.L. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annual Review of Pharmacology and Toxicology 1999, 39:19-52.
69. Wildeboer K.M., Zheng L., Choo K.S., Stevens K.E. Ondansetron results in improved auditory gating in DBA/2 mice through a cholinergic mechanism. Brain Research 2009, 1300:41-50.
70. Xiao P.F., Cheng L., Wan Y., Sun B.L., Chen Z.Z., Zhang S.Y., Zhang C.Z., Zhou G.H., Lu Z.H. An improved gel-based DNA microarray method for detecting single nucleotide mismatch. Electrophoresis 2006, 27:3904-3915.
71. Xiao P., Huang H., Zhou G., Lu Z. Gel immobilization of acrylamide-modified single-stranded DNA template for pyrosequencing. Electrophoresis 2007, 28:1903-1912.
72. Young D.A., Waldo M., Ruttledge J.H., Freedman R. Heritability of inhibitory gating of the P50 auditory-evoked potential in monozygotic and dizygotic twins. Neuropsychobiology 2001, 33:113-117.